Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the ...
Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, ...
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success ...
Eli Lilly built up $1.5 billion in pre-launch inventory for its experimental oral weight-loss drug orforglipron, according to a regulatory filing.
The EY deals leader discusses recent findings and trends from 2025.
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, discusses how Soley uses human cells to guide drug discovery, ...
In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum ...
Today, that includes practices that exert price pressures designed to favor domestic companies, such as value-based ...
Novo Nordisk, the manufacturer of Wegovy, responded strongly to the initial launch of Hims & Hers’ compounded semaglutide ...
In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and ...
To be successful in the pharmaceutical industry, leaders must be willing to take risks. During his conversation with Pharmaceutical Executive, Leonard Mazur kept coming back to this point. According ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results